Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

HANALL BIOPHARMA CO.,LTD

한올바이오파마009420KOSPISector: Pharma & Biotech
₩55,1007.71%Market cap ₩2.88TAs of Sep 1, 2026 close · updated once daily
Market cap
₩2.88T
#138 in KOSPI
Loss
PER not computable
17.79x
Sector median 1.61x
0.0%
Sector median 0.0%
C
Grade C42.3 ptsBottom 34% of 2,523 graded stocksMethodology v2.0
Financial strength
54.1/100
Growth momentum
38.7/100
Price attractiveness
32.0/100
Shareholder Return
37.5/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCCurrentDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band C with a total score of 42.3 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩29,100High ₩70,700
Latest close
Price change by period
1W
9.20%
1M
26.90%
3M
5.10%
1Y
89.30%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

54.1/100
How much debt does it carry relative to equity?
39.3%
Sector median 51.6%
Sector lowhighTop 36.6% in sector
Can it cover what's due within a year?
191.0%
Sector median 191.7%
Sector lowhighBottom 49.6% in sector
How much of revenue becomes profit?
-0.6%
Sector median -2.4%
Sector lowhighTop 48.6% in sector
How much did it earn on its own capital?
-3.4%
Sector median -4.5%
Sector lowhighTop 48% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

38.7/100
How much did revenue grow in a year?
11.7%
Sector median 6.4%
Sector lowhighTop 36.6% in sector
Has it grown steadily over three years?
12.2%
Sector median 4.9%
Sector lowhighTop 25.5% in sector
Did core profits grow in a year?
-497.4%
Sector median 3.6%
Sector lowhighBottom 3.8% in sector
Are core profits higher than three years ago?
-160.8%
Sector median 3.5%
Sector lowhighBottom 13.2% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

32.0/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 44.7% in sector
Is the price expensive relative to book value?
17.79x
Sector median 1.61x
Sector lowhighBottom 8.7% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
1,459,781 shares (2.7% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 3 met · 6 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩5.6B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩2.3B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-0.8% → -2.6%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩2.3B vs -₩5.6B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
20.9% → 28.2%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
245.8% → 191.0%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
52,240,638 → 52,240,638
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
0.2% → -0.6%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.58x → 0.73x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026C

Methodology version change (v2.0 applied)

Jul 15, 2026CVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →